Christine Sadlowski talks to Dr. Mikhail N. Kosiborod about the results of the STEP-HFpEF DM trial, which show functional and weight-loss benefits of semaglutide in patients with obesity-related heart failure and preserved ejection fraction who also have type 2 diabetes.